Top Clinical Trials companies in Hong Kong by Debt to Equity Ratio
Hong Kong
# |
Name |
Debt to Equity Ratio |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
0.42
|
Dec. 31, 2023 | USD 0.22 | -1.18% |
|
Hong Kong |
|
| 2 |
0.22
|
Dec. 31, 2023 | USD 0.37 | 4.31% |
|
Hong Kong |
|
| 3 |
0.12
|
Dec. 31, 2023 | USD 2.68 | -1.44% |
|
Hong Kong |
|
| 4 |
0.10
|
Dec. 31, 2023 | USD 0.16 | -3.21% |
|
Hong Kong |
|
| 5 |
0.01
|
Dec. 31, 2023 | USD 5.25 | -2.96% |
|
Hong Kong |
Frequently Asked Questions
-
Which Clinical Trials company in Hong Kong has the highest Debt to Equity Ratio ?
The Clinical Trials company in Hong Kong with the highest Debt to Equity Ratio is Frontage Holdings Corporation (HKSE: 1521.HK) at 0.42.
-
Which Clinical Trials company in Hong Kong has the lowest Debt to Equity Ratio ?
The Clinical Trials company in Hong Kong with the lowest Debt to Equity Ratio is Prenetics Global Limited (NasdaqGM: PRE) at 0.01.
-
What are the top 10 Clinical Trials companies in Hong Kong by Debt to Equity Ratio ?
The top 10 Clinical Trials companies in Hong Kong by Debt to Equity Ratio are Frontage Holdings Corporation, Sirnaomics Ltd., HUTCHMED (China) Limited, Lee's Pharmaceutical Holdings Limited and Prenetics Global Limited.
-
What are the bottom 10 Clinical Trials companies in Hong Kong by Debt to Equity Ratio ?
The bottom 10 Clinical Trials companies in Hong Kong by Debt to Equity Ratio are Prenetics Global Limited, Lee's Pharmaceutical Holdings Limited, HUTCHMED (China) Limited, Sirnaomics Ltd. and Frontage Holdings Corporation.
